Standout Papers

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial 2025 202616
  1. Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial (2025)
    Jordana E. Hoppe, Ajay S. Kasi et al. The Lancet Respiratory Medicine

Immediate Impact

1 from Science/Nature 61 standout
Sub-graph 1 of 20

Citing Papers

“The NET effect”: Neutrophil extracellular traps—a potential key component of the dysregulated host immune response in sepsis
2025 Standout
Endoplasmic reticulum stress as a driver and therapeutic target for kidney disease
2025 Standout
10 intermediate papers

Works of Renée Jensen being referenced

Progression of Lung Disease in Preschool Patients with Cystic Fibrosis
2017
Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function
2010
and 4 more

Author Peers

Author Last Decade Papers Cites
Renée Jensen 1050 252 29 112 27 1.1k
Gregg L Ruppel 1095 536 26 58 30 1.3k
Kathryn Ramsey 956 221 60 160 55 1.3k
Jan Willem J. Lammers 735 232 12 103 30 1.1k
J Stroobant 748 156 16 140 18 864
B. R. Celli 912 304 26 37 20 1.0k
I. Court-Fortuné 922 375 6 82 18 1.1k
Claude S. Farah 916 788 16 78 52 1.2k
Piero Emilio Balbo 736 434 10 119 41 1.2k
N. B. Pride 1009 674 28 63 44 1.3k
A Zapletal 1028 579 54 155 43 1.3k

All Works

Loading papers...

Rankless by CCL
2026